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Abstract
Objective: Various techniques to reduce air space after pulmonary lobectomy especially for lung
cancer have been an important concern in thoracic surgical practice. The aim of this study was to
assess the effectiveness of Botulinum toxin A (BTX-A) injection into the diaphragm to reduce air
space after right lower pulmonary lobectomy in an animal model.
Methods: Twelve male New Zealand rabbits were randomly allocated into two groups. All animals
underwent right lower lobectomy. Then, normal saline of 0,1 ml and 10 units of 0,1 ml Botulinum
toxin type A were injected into the muscular part of the right hemidiaphragm in control (n = 6)
and BTX-A groups (n = 6) respectively. Residual air space and diaphragmatic elevation were
evaluated with chest X-ray pre- and postoperatively. Diaphragmatic elevation was measured as a
distance in millimetre from the line connecting the 10th ribs to the midpoint of the right
hemidiaphragm.
Results: The mean diaphragmatic elevation in BTX-A and control groups were 7.0 ± 2.5 and 1.3
± 1.2 millimetres respectively. Diaphragmatic elevations were significantly higher in BTX-A group
(p = 0.0035).
Conclusion: Intraoperative Botulinum toxin type A injection may reduce postlobectomy spaces
effectively via hemidiaphragmatic paralysis in rabbits. Further studies are needed to validate the safe
use of Botulinum toxin type A in human beings.
Introduction
Lung resection alone is the most effective therapy for the
patients with non-small cell lung carcinoma limited to the
lung without distant metastasis. Complete resection is the
goal of all operations for lung cancer. Every patient with
locoregional lung cancer should be approached as a
potential candidate for resection. For patients with ade-
quate lung function, the current standard cancer resec-
tions include lobectomy, bronchoplastic lobectomy,
bilobectomy and pneumonectomy, based on the extent of
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disease. The appropriate operation depends on the clini-
cal and surgical stage of the tumor. Lobectomy is the ideal
operation for resection of a lung cancer confined to the
parenchyma of a single lobe[1,2].
After a lobectomy, the pleural space is drained routinely.
Approximately 10% of persistent spaces become compli-
cated with empyema or bronchopleural fistula). Lung
lobectomies especially in the presence of fibrotic paren-
chymal disorders often leave a pleural space, and the
remaining lobe or lobes may not be sufficient to fill the
ipsilateral hemithorax. Residual air space and prolonged
air leak after pulmonary lobectomies can potentially
cause serious complications such as bronchopleural fis-
tula and empyema, requiring longer hospital stay and
increased health costs. Although it is not universally
accepted among thoracic surgeons, reducing postlobec-
tomy space could theoretically be useful in preventing the
above-mentioned complications. In this respect, several
manoeuvres can be used to attempt to decrease the size of
the hemithorax including pleural tents, muscle flaps,
pneumoperitoneum and phrenic nerve manipulation [1-
4].
Botulinum toxin type A (BTX-A) is an extremely potent
neurotoxin that interacts selectively with cholinergic neu-
rons to inhibit the presynaptic release of the neurotrans-
mitter acetylcholine [5]. BTX-A is currently used for
cosmetic and therapeutic goals for years, but to our
knowledge, has not been reported for the treatment of
postlobectomy spaces in literature so far. The aim of our
present study was to evaluate whether BTX-A can be effec-
tive for hemidiaphragmatic paralysis to prevent post-
lobectomy space in an animal model.
Materials and methods
The protocol was approved by the Institutional Animal
Care and Use Committee, and all animals were housed in
the facilities of the Medical Faculty of Pamukkale
University.
Animals
This study was carried out on twelve male New Zealand
rabbits weighing between 1.5–2.0 kg. The animals were
housed in wire bottom cages at 21–24°C room tempera-
ture with 12-hour light dark cycle. All animals were fed on
standard laboratory diet and water but received only water
for 12 h before surgery.
After an overnight fast, the rabbits were anesthetized by an
intramuscular injection of ketamine, 35 mg/kg and xyla-
zine 5 mg/kg. After cardiac monitorization and endotra-
cheal intubation, ventilation was maintained artificially
(SAR-830 Rodent ventilator, Geneq Inc., Montreal,
Canada).
Surgical procedure
The right chest wall was shaved, and the animal placed in
a left side down position. A skin incision of 3–4 centime-
tre in length was made on the right anterolateral chest
wall under aseptic conditions. The muscles in the 6th inter-
costal space were bluntly dissected to expose the right tho-
racic cavity. Right lower lobectomy was performed by
ligation of bronchial artery, vein and bronchi with 2/0 silk
suture. Then, animals were randomly allocated to two
groups. Following right lower lobectomy, the animals in
Group 1 (n = 6) served as controls, and 0,1 ml of 0.09%
NaCI was injected into the medial and lateral muscular
part of the right hemidiaphragm. The animals in Group 2
(n = 6) were injected with 10 U (0, 1 ml) BTX-A (BOTOX®,
Allergan Pharmaceutical Ltd., Ireland) into the same
region as in Group 1. All injections were made using a 26-
gauge needle attached to a sterile 1 ml syringe. All animals
had a 10F chest tube placed along the diaphragm and for
the following two hours aspirated intermittently and chest
tube was removed after having negative pressure. Both
Postoperative 7th day chest radiograph of a rabbit of BTX-A  group Figure 1
Postoperative 7th day chest radiograph of a rabbit of BTX-A 
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groups received single dose prophylactic antibiotic, and
received diclofenac sodium for postoperative analgesia for
3 days.
Postoperative period
After the surgery, the rabbits were closely monitored for
clinical evidence of pain (vocalisation, tachypnea, and
restlessness) for seven days. Chest radiographs were taken
for evaluation of diaphragmatic elevation, residual air
space and complications. X-rays were taken during in
inspiration. Since the onset of paralytic effect of Botuli-
num toxin type A begins in 2nd day, diaphragmatic eleva-
tion was evaluated radiographically in four consecutive
antero-posterior-chest radiographs (preoperatively, post-
operatively, 3rd and 7th day). All the roentgenograms were
taken at a 90 cm distance from the cassette while animals
were in erect position. Diaphragmatic elevation was meas-
ured as a distance in millimetre from the line connecting
the 10th ribs to the midpoint of the right hemidiaphram.
Reversal of paralysis was observed by fluoroscopic exami-
nation of diaphragmatic movements.
Statistical analysis
The results are expressed as mean and ± standard devia-
tion (SD). Differences among the groups were evaluated
using Mann-Whitney U test. A P value of less than 0.05
was considered significant.
Results
There were no respiratory distress, prolonged air leak and
any other complications requiring treatment in any
group. Two animals in BTX-A group had about less than
10% increase in respiratory rate at the 3rd day and nor-
malised at the 4th day (From about 70 to 80 breaths per
minutes). There was no changes in dietary patterns, and
neither vocalisation nor agitation in any animal.
Immediate postoperative and 3rd  day roentgenograms
revealed no complications such as hemothorax, mediasti-
nal shift and atelectasis. Minimal residual air space in the
base of right hemidiaphragm was detected in 3rd day
roentgenograms of two rabbits in BTX-A and three rabbits
in control groups. There was no residual air space In BTX-
A group but was still remaining in 2 rabbits of control
group in 7th day radiographs.
The mean preoperative and postoperative 7th day meas-
urements of diaphragmatic heights are shown in Table 1
for both groups. The mean right hemidiaphragmatic ele-
vations were 7.0 ± 2.5 in BTX-A (Figure 1) and 1.3 ± 1.2 in
control (Figure 2) groups. Diaphragmatic elevations were
significantly different (p = 0.0035) between groups. Fluor-
oscopic examination of diaphragmatic movements
revealed that paralyses reversed in 8–12 weeks.
Discussion
Some of the major factors delaying early hospital dis-
charge following pulmonary lobectomy for lung cancer
Table 1: Diaphragmatic heights, and diaphragmatic elevation differences in both groups (mean ± SD).
Control group BTX-A group P value
Preop diaphragmatic heights (mm) 23.8 ± 5.4 24.8 ± 5.7 NS
Postop 7th day diaphragmatic 
heights (mm)
25.2 ± 4.4 31.8 ± 4.3 0.045
Elevation difference (mm) 1.3 ± 1.2* 7.0 ± 2.4 0.0035
Postoperative 7th day chest radiograph of a rabbit of control  group Figure 2
Postoperative 7th day chest radiograph of a rabbit of control 
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can be secondary to the adverse consequences of post-
lobectomy space. With increasing concern for quality of
medical care, length of hospital stay, and cost of health
care delivery, it has become the responsibility of the sur-
geon to control all factors that lead to a prolonged
hospitalization.
Although several techniques have been used for preven-
tion of postlobectomy space, optimal methods have not
been described. Among these methods diaphragmatic ele-
vation techniques have been used [1,2]. Phrenic nerve
paralysis by crushing or local anaesthetic injection are
some of the applied techniques for this purpose. Compli-
cation of permanent paralysis by crushing or ineffective-
ness of short term paralysis by local anaesthetic injection
reduces the usefulness of diaphragmatic elevation
method. In general, diaphragmatic paralysis leads up to
20% loss of in pulmonary functions in adults with fully
expanded normal lungs, in which elevated diaphragm will
compress the expanded lung [6-8]. However when a
patient had a lobectomy, diaphragmatic paralysis will not
collapse an expanded lung, but instead obliterates a dead
space.
In several rabbit studies, botulinum toxin A has been used
as 5 to 10 units for relaxation of different muscles [9,10].
In the study of Aoki, the safety margin of BTX-A was deter-
mined as 13.9 ± 1.7 U/kg in mice [11]. As the duration of
act of BTX is dose dependent, 10 U of BTX injection per
animal was preferred into the diaphragm, which was safe
and provided sufficient paralysis [12].
Botulinum toxin type A has an average clinical onset of
action approximately 12 to 72 hours after injection, with
a peak effect at one week. Then, plateau effect continues
for 1 to 2 months [13]. For this reason, we took radio-
graphs at the 3rd and 7th day for the evaluation of dia-
phragmatic elevation. We detected significant
diaphragmatic elevation in the BTX-A group at day 7.
Fluoroscopic examination of diaphragmatic movements
revealed that paralysis reversed in 8–12 weeks. Our results
are generally in concordance with these studies.
In this study, we showed that injection of BTX into the
diaphragm can provide effective elevation for the preven-
tion of postlobectomy space in an animal model.
Further studies are now required to evaluate its effective-
ness in the clinical setting, particularly after pulmonary
resection for lung cancer.
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